Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0FXANL)
| ADC Name |
ABBV-637
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
ABBV-637
Click to Show/Hide
|
|||||
| Organization |
AbbVie (Top20 MNC) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-EGFR antibody
|
Antibody Info | ||||
| Antigen Name |
Epidermal growth factor receptor (EGFR)
|
Antigen Info | ||||
| Payload Name |
BCL-xL inhibitor
|
Payload Info | ||||
| Payload Target |
Bcl-2-like protein 1 (BCL2L1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Disease control rate (DCR) |
65
73 % |
|||
| Patients Enrolled |
Key eligibility: Adults with solid tumors (Part 1) or EGFR-altered NSCLC (Parts 2-3), measurable disease (RECIST 1.1), ECOG 0-1. Exclusions: cardiac dysfunction (NYHA ≥2 within 6 months), unresolved Grade 2+ toxicities, or (for Part 3) history of ILD/pneumonitis requiring steroids. Requires progression after prior therapies (platinum-based for Part 2, osimertinib for Part 3).
Click to Show/Hide
|
||||
| Administration Dosage |
Participants will receive escalating doses of ABBV-637 in 28-day cycles.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT04721015 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors | ||||
| Primary Endpoint |
Primary objectives evaluate safety through AE/SAE incidence (up to 3 years) and efficacy via ORR (confirmed CR/PR per RECIST 1.1 by investigator assessment) in Parts 2 and 3.
|
||||
| Other Endpoint |
Secondary endpoints assess ORR in Part 1 (3 years), DOR (time from CR/PR to progression/death) for ABBV-637 monotherapy (12 months) and combination therapies (20 months), PFS (time to progression/death) and OS (time to death) for docetaxel/osimertinib combinations (20 months).
|
||||
References